Latest Headlines

Latest Headlines

Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2s

The  New England Journal of Medicine  has laid out the data from a cardiovascular outcomes trial of Sanofi's GLP-1 diabetes hopeful Lyxumia, and the good news for the French drugmaker is that the drug didn't raise the rate of major cardiovascular events in patients with acute coronary syndrome. But it didn't lower it, either.

No change in CV risk for ACS patients on Sanofi's Lyxumia

Back in June, researchers unveiled details of the ELIXA trial, which put Sanofi's Lyxumia in the clear as far as cardiovascular safety risks go. Now, a new analysis of the study shows that in Type 2 patients with acute coronary syndrome, the diabetes med didn't increase the rate of cardiovascular events--but it didn't decrease it, either.

Are CV studies worth it for diabetes meds? After Merck and Sanofi's recent successes, some say no

Some industry watchers are wondering whether those large, expensive trials--which aren't long enough to establish long-term outcomes--were worth it.

Sanofi's diabetes franchise one step closer to U.S. Lyxumia launch

Sanofi can go back to the FDA with Lyxumia. The French drugmaker got good news from a cardiovascular outcomes study, required by the FDA before it would approve the diabetes drug.

Newly minted Sanofi diabetes med fails to impress German pricing regulators

Sanofi's new diabetes drug hit a setback in Germany. The country's increasingly strict pricing regulators say Lyxumia delivers "no additional benefit" compared with existing drugs. If the decision sticks, then Sanofi would lose the power to price Lyxumia at a brand-name premium.

Sanofi stands up for diabetes therapy in crowded GLP-1 contest

Sanofi is making a case for why its experimental diabetes drug Lyxumia stands out from existing GLP-1 therapies, as the French drug giant eyes the new med to build up its Lantus-led diabetes franchise amid relentless competition.

Sanofi R&D chief spotlights diabetes strategy amid Amylin bid buzz

In one of the worst kept secrets in the industry, Sanofi has been in the scrum of potential buyers forming around Amylin in recent weeks.